Are breast cancer molecular classes predictive of survival in patients with long follow-up?

16Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this study we investigate the clinical outcomes of 305 breast cancer (BC) patients, aged 55 years or younger, with long follow-up and according to intrinsic subtypes. The cohort included 151 lymph node negative (LN-) and 154 lymph node positive (LN+) patients. Luminal A tumors were mainly LN-, well differentiated, and of stage I; among them AR was an indicator of good prognosis. Luminal B and HER2 positive nonluminal cancers showed higher tumor grade and nodal metastases as well as higher proliferation status and stage. Among luminal tumors, those PR positive and vimentin negative showed a longer survival. HER2-positive nonluminal and TN patients showed a poorer outcome, with BC-specific death mostly occurring within 5 and 10 years. Only luminal tumor patients underwent BC death over 10 years. When patients were divided in to LN- and LN+ no differences in survival were observed in the luminal subgroups. LN- patients have good survival even after 20 years of follow-up (about 75%), while for LN+ patients survival at 20 years (around 40%) was comparable to HER2-positive nonluminal and TN groups. In conclusion, in our experience ER-positive breast tumors are better divided by classical clinical stage than molecular classification, and they need longer clinical follow-up especially in cases with lymph node involvement. © 2013 Danae Pracella et al.

Cite

CITATION STYLE

APA

Pracella, D., Bonin, S., Barbazza, R., Sapino, A., Castellano, I., Sulfaro, S., & Stanta, G. (2013). Are breast cancer molecular classes predictive of survival in patients with long follow-up? Disease Markers, 35(6), 595–605. https://doi.org/10.1155/2013/347073

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free